Cefenil 50 mg/ml Powder and Solvent for Solution for Injection for Cattle and Pigs

Pajjiż: Irlanda

Lingwa: Ingliż

Sors: HPRA (Health Products Regulatory Authority)

Ixtrih issa

Ingredjent attiv:

Ceftiofur

Disponibbli minn:

Norbrook Laboratories Limited

Kodiċi ATC:

QJ01DD90

INN (Isem Internazzjonali):

Ceftiofur

Dożaġġ:

50 milligram(s)/millilitre

Għamla farmaċewtika:

Powder for solution for injection

Tip ta 'preskrizzjoni:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupp terapewtiku:

Cattle, Pigs

Żona terapewtika:

ceftiofur

Indikazzjonijiet terapewtiċi:

Antibacterial

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2009-09-25

Karatteristiċi tal-prodott

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Cefenil 50 mg/ml Powder and Solvent for Solution for Injection for
Cattle and Pigs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Powder vial contains:
ACTIVE SUBSTANCE
Ceftiofur (as ceftiofur sodium)
1g
Or
Ceftiofur (as ceftiofur sodium)
4g
Solvent contains: Water for Injection
One ml of reconstituted solution contains:
ACTIVE SUBSTANCE
Ceftiofur (as ceftiofur sodium)
50mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder and solvent for solution for injection.
Powder: off white to brown coloured powder.
Solvent: clear, colourless, solution.
Reconstituted solution: clear solution, free of particulates.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle and pigs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Cattle
Treatment of cattle with acute bacterial respiratory disease in which_
Mannheimia haemolytica,_
_Pasteurella multocida_
_or Histophilus somni_ sensitive to ceftiofur are involved.
Treatment of cattle with acute interdigital necrobacillosis (foul in
the foot) in which_ Fusobacterium necrophorum_ and
_Bacteroides melaninogenicus_ are involved.
Pigs
Treatment
of
pigs
with bacterial
respiratory disease in which_ Actinobacillus_
_(Haemophilus)_
_pleuropneumoniae,_
_Pasteurella multocida_ and/or_ Streptococcus suis_ sensitive to
ceftiofur are involved.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_4_
_/_
_0_
_9_
_/_
_2_
_0_
_1_
_4_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_
                                
                                Aqra d-dokument sħiħ
                                
                            

Fittex twissijiet relatati ma 'dan il-prodott